Company

BiOrion is a Dutch clinical stage biopharmaceutical company engaged in developing PET-imaging diagnostics and targeted radiotherapeutics for fibrotic diseases. We are testing our first PET imaging diagnostic in a clinical study in patients with either liver or heart fibrosis. When appropriate, the program is extended to patients with either lung fibrosis or colon cancer.

Read more

Target

Fibrotic tissue, as present in e.g. heart fibrosis and in solid cancer stroma, is characterized by myofibroblast-specific overexpression of the PDGF-ß-receptor. This over-expressed receptor allows myofibroblast-specific targeting and delivery of imaging and therapeutic radionuclides or antifibrotic drugs, thereby leaving healthy tissues unaffected. As the PDGF-ß-receptor appears early during fibrogenesis and declines rapidly during fibrolysis, it is a sensitive diagnostic biomarker for disease-monitoring and therapeutic strategies. Therefore, our novel non-invasive PET imaging diagnostics may be superior to other existing diagnostics for fibrosis in the market.

Read more

Pipeline

BiOrion runs two active development programs. Cardiscan®, is a PET imaging diagnostic where the PET radionuclide 68-Gallium is conjugated to a PDGF-ß-receptor binding bicyclic peptide to identify patients with cardiac fibrosis. This program will be extended to patients with either liver, lung or kidney fibrosis. In the PET imaging diagnostic Oncoloscan®, the PET radionuclide 68-Gallium is conjugated to a PDGF-ß-receptor binding single domain antibody (VHH) whereas in Oncoluthera® the radionuclide 177-Lutetium is conjugated to this identical single domain antibody. The latter two will be developed for patients suffering from metastasized cancer with fibrotic stroma. This single domain antibody program is in preclinical stage. A clinical phase 1-2a study is expected to enroll first patients in 2022.

Read more

 News

More News >>

 Events

no event

 Partners